Please assess the completion status of the following clinical trial:

Trial Title: The Duration Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy~* Baseline hemoglobin value \>= 11 g/dL and \<= 12 g/dL unrelated to transfusion~* Female patients with reproductive potential must have a negative serum pregnancy test at screening. Patients must have signed an informed consent~Exclusion Criteria:~* Uncontrolled hypertension~* History (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder~* Transfusion within 28 days prior to first dose~* Planned myelosuppressive chemotherapy or radiation during study and no prior chemotherapy within 8 weeks or radiation within 4 weeks of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).